Biogen, Genentech Head To June Trial Over MS Drug Royalties
A California federal judge on Tuesday denied Biogen's bid for summary judgment in a high-stakes contract fight with Roche Holding AG subsidiary Genentech over patent royalties on multiple sclerosis drug sales,...To view the full article, register now.
Already a subscriber? Click here to view full article